NCT02807558 - A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

Tamibarotene

Administered as oral tablets

DRUG

Azacitidine

Administered via intravenous (IV) or subcutaneous (SC) infusion

DRUG

Daratumumab

Administered via IV infusion

Trial Locations (26)

54511

Centre Hospitalier Universitaire Nancy, Vandœuvre-lès-Nancy

94805

Institut Gustave Roussy, Villejuif

Unknown

Hartford

Miami

Iowa City

Boston

Ann Arbor

New York

Rochester

Durham

Cleveland

Portland

Allentown

Pittsburgh

Nashville

Houston

CHU Amiens, Amiens

Centre Hospitalier de la Côte basque, Bayonne

Centre Hospitalier Universitiaire Hopital Avicenne, Bobigny

Hospital Morvan, Brest

Centre Hospitalier de Versailles - Hôpital André Mignot, Le Chesnay

Centre hospitalier Lyon Sud, Lyon

Centre Hospitalier Universitaire Nantes, Nantes

Nice Hospital, Archet Hospital 1 Clinical Hematology Service, Nice

Hopital Saint Louis, Paris

Hôpital Haut Leveque, Centre Francois Magendie, Pessac